Partnership Will Provide 1,200 Cleveland Metropolitan School District Students With Eye Care at No Cost - Vision To Learn is Building on Its Well-Established Program Nationally to Help More Kids in Ohio
Read MoreSuccessful completion of 14-day gas-to-power trial at Pathfinder production hub delivers ~1.5 MW/hour of electricity to power two bitcoin mining containers;
The 14-day trial delivered ~85% system uptime and, since the end of the trial, the system has achieved greater than 90% uptime;
AXP has secured the support of NASDAQ-listed Bitcoin miner BitFuFu, Inc. (NASDAQ: FUFU, FUFU.WS) for the next phase of expansion at Pathfinder;
BitFuFu will supply additional ASIC Miners and other equipment to support the next phase of expansion, with AXP focused on delivering gas-to-power and site services;
All parties are now committed to establishing power generation output of 25MW/hour by the end of CY2025 for a significant scale up of bitcoin mining operations, powered by Pathfinder's ~750 Bcf of contingent gas resources;
The parties are now assessing further expansion opportunities.
New 45-Minute Sound Therapy Sessions Following Ketamine Treatment Offer Deeper Relaxation, Emotional Release, and Enhanced Healing
Read More
Pre-eminent Peer-Reviewed Cybercrime Conference Examines Physical Impact of Cybercrime Driven by AI Innovations -- Underwritten by a Newly Wealthy Criminal Culture
Read More
- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -
- The Company recently entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics (recently merged with Crown Laboratories) to study DMT410 for the treatment of axillary hyperhidrosis -
- Raised $2.55 million in gross proceeds from a private placement financing in January 2025, including participation from Dermata's Chief Executive Officer, Chief Financial Officer, and certain members of the Company's board of directors -
